Sometimes it is not possible or desirable to conduct a trial for a vaccine. Following stringent processes by manufacturers and clinical trials, an evaluation can only be conducted as a modelling exercise. Consider the investigation in to the cost effectiveness of including boys in a human papillomavirus vaccination programme.
Kim JJ and Golding SJ. 2009. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.BMJ, 339:b3884 [CAM628 Library Reading List]
1. What models did the team use?
2. What strategies were dominated in the cost-effectiveness analysis?
3. How did the authors investigate any uncertainty surrounding their model parameters?

301 comments on “Stringent processes by manufacturers and clinical trials

Leave a Reply

Your email address will not be published. Required fields are marked *